Specifics on Active & Closed Studies

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects with Mild Alzheimer's Disease

Study Status: 
Closed
Study Description: 

What is the purpose of this study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BMS241027, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called tau, in the fluid surrounding the brain. We hope that BMS241027 can decrease the levels of tau.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with mild Alzheimer's disease

-- are between the age of 50 and 90

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are willing to undergo MRI and lumbar punctures

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.

 

Please see the attached study description for more information.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

The Risk Evaluation and Education for Alzheimer's Disease (REVEAL) Study

Study Status: 
Closed
Study Description: 

WHAT IS THE REVEAL STUDY?

Many people with mild memory concerns wonder whether they will develop Alzheimer's disease (AD).

The REVEAL study is a multi-center, NIH-funded research project based at Brigham and Women's Hospital.

The goal of REVEAL is to use genetic information to help predict whether someone with mild memory problems will develop AD.

 

WHO IS ELIGIBLE TO PARTICIPATE?

You may participate if you:

* Are at least 55 years old

* Speak and read English

* Have been given a diagnosis of Mild Cognitive Impairment (MCI)

* Have a close friend or family member to be a study partner

 

More information is attached.

Study Coordinator(s): 

Sehily JaimesTel:  617-643-5200

Neural Correlates of Olfactory Function in Neurodegenerative Disease

Study Status: 
Closed
Study Description: 

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in individuals with asymptomatic prodromal Alzheimer's disease, clinical Alzheimer's disease, Mild Cognitive Impairment, Dementia with Lewy Bodies, and Frontotemporal Dementia.

 

If you qualify, you will be asked to take a test that measures your ability to identify a group of everyday odors. You will also be asked to undergo an MRI brain scan. While we take pictures of your brain, we will present you with odors and ask you to let you know when you can smell them.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Patients with Mild to Moderate Alzheimer's Disease

Study Status: 
Closed
Study Description: 

The purpose of this clinical trial is to evaluate the efficacy and safety of Bapineuzumab, a drug that has the potential to treat Alzheimer's disease. Bapineuzumab is a vaccine against amyloid (the protein deposits in the brain that are believed to cause Alzheimer's disease). It is hoped that Bapineuzumab will attach to the amyloid protein in the brain and help the body to remove it and in doing so help stop the progression of Alzheimer's disease.

 

WHO IS ELIGIBLE?

We are looking for participants who:

--have been diagnosed with mild-moderate Alzheimer's disease

--are between the age of 50 and 88

--have a reliable caregiver or family member who is able to accompany them to study visits

--are in stable medical condition

--are willing to undergo genetic testing

--are willing to undergo MRI scans

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to participate in this study and can continue taking these medications during the study.

 

More information is attached.

Study Coordinator(s): 

Caroline A. Sullivan, BA

Tel:  617-643-5200

Olfactory Deficits in Neurological Disease

Study Status: 
Active
Study Description: 

We are seeking healthy adults, aged 18 or older, to participate in a research study. The goal of the study is to examine olfactory function (or the sense of smell) in healthy individuals and in preclinical and clinical subjects with Alzheimer's Disease, Dementia with Lewy Bodies, or Frontotemporal Dementias.

 

If you qualify, you will be asked to undergo tests that measure your ability to discriminate, identify, remember, and evaluate a group of everyday odors. The study will take place at the Departments of Neurology or Psychiatry of the Massachusetts General Hospital (either on the Charlestown Navy Yard or the main campus of the hospital). It will take approximately one hour to complete the tests.

 

You will be asked to do this once a year. You will not be paid for participating in the study.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Phase 2, Multi-Center, 24-Month, Randomized, Third-Party Unblinded, Placebo-Controlled, Parallel-Group Amyloid Imaging Positron Emission Tomography (PET) and Safety Trial of ACC-001 and QS-21 Adjuvant in Subjects with Early Alzheimer's Disease

Study Status: 
Closed
Study Description: 

WHAT IS THE PURPOSE OF THIS STUDY?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of ACC-001, a drug that has the potential to treat early Alzheimer's disease. ACC-001 is a vaccine against amyloid. In a healthy brain, amyloid is broken down and eliminated. In early Alzheimer's disease, amyloid fragments gather and from hard plaques. Doctors think that the amyloid plaques cause symptoms like memory loss and confusion.

QS-21 is an adjuvant. An adjuvant is a substance that helps to stimulate the body's immune system to produce antibodies. Antibodies are a type of protein made by white blood cells to destroy foreign substances in the body. It is hope that ACC-001 alone or when mixed with QS-21 will act a vaccine to help the body make antibodes to destroy the amyloid protein in the brain.

 

WHO IS ELIGIBLE?

We are looking for participants who:

* have early onset Alzheimer's disease or have changes in memory also known as Mild Cognitive Impairment (MCI)

* are between the age of 50 and 80

* have a reliable caregiver or family member who is able to accompany them to study visits

* are in stable medical condition

* are willing to undergo a lumbar puncture (spinal tap)

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study. You do not have to be on these medications to take part in the study.

 

More information is attached.

Study Coordinator(s): 

Caroline A. Sullivan, BA

Tel:  617-643-5200

Brain Imaging Markers in Mildly-Impaired Cognition

Study Status: 
Closed
Study Description: 

We are in need of volunteers to participate in a memory and high blood pressure study at Massachusetts General Hospital. We would greatly appreciate your help!

 

You may be eligible if you...

-Are age 60 or older

-Have high blood pressure or are taking blood pressure medication

-Have memory concerns

-Have someone close to you who can answer questions about your daily activities

 

This two year research study involves:

-Evaluation including memory tests each year

-Brain imaging at study entry and at 2 years

 

You will receive:

-$40 each clinic visit for you and your study partner

-$50 for MRI visits and $100 for PET imaging visits for you

 

Please contact the Gerontology Research Unit (Tel:  617-643-5200) if you are interested in participating.

 

Thank you!

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

The Harvard Aging Brain Study

Study Status: 
Closed
Study Description: 

We are seeking healthy adults, 65 to 90 years of age to participate in a research study. The purpose of the study is to develop ways for understanding brain changes affecting memory and thinking that occur with age.

 

Participants will be asked questions about their memory and thinking and must have a friend or relative who can answer 30 minutes of questions about your day-to-day activities.  If you qualify, you will be asked to have 8 brain scans at year 1 and 3, follow-up memory and thinking testing as well as blood draws annually for five years (at 12, 24, 36, 48 & 60 monhts) after the initial visit.

 

You may also participate in an optional study where you will have 2 lumbar punctures (spinal taps).

 

All evaluations will be free of cost and reimbursement for time and transporation is $1600.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Implications of Amyloid Deposition in Clinically Normal Older Individuals

Study Status: 
Active
Study Description: 

Please click on the study title and see the attached memo.

Study Coordinator(s): 

Katherine M. Frishe, BA

Tel:  617-525-9554

Alzheimer's Disease Neuroimaging Initiative - Grand Opportunity

Study Status: 
Active
Study Description: 

Please click on the study title and see the attached memo.

Study Coordinator(s): 

Natacha Lorius, BA

Tel:  617-643-0147

Syndicate content